Lymphedema Market

Market Overview:

The 7 major lymphedema markets reached a value of US$ 647.9 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 1,405.7 Million by 2034, exhibiting a growth rate (CAGR) of 7.3% during 2024-2034.

The lymphedema market has been comprehensively analyzed in IMARC's new report titled "Lymphedema Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Lymphedema refers to a chronic condition that occurs when the lymphatic system is unable to properly drain lymphatic fluid from the body's tissues, leading to fluid buildup and swelling in the affected area. It usually affects the arms or legs, although it can also affect the genitalia, chest wall, belly, and neck. Depending on the causative factor, the disease is classified into primary and secondary lymphedema. Repeated episodes of this condition can cause other complications, such as skin infections, lymphangitis, deep vein thrombosis, psychological disorders, etc. The common symptoms associated with lymphedema include soft tissue swelling, edema, skin changes including discoloration, dermal thickening, verrucous hyperplasia, hyperkeratosis, ulcers, etc. The diagnosis of this ailment primarily involves the evaluation of underlying indications and physical examination. The healthcare professional may also perform a magnetic resonance imaging (MRI) scan, computerized tomography (CT) scan, and doppler ultrasound scan to deeply examine the lymphatic system and assess the extent of disease staging. Additionally, lymphoscintigraphy, in which a radioactive dye is injected into the lymphatic system to identify any blockages, is used to confirm a diagnosis.

The increasing cases of infections and inflammatory diseases that damage the tissue around the lymph nodes or vessels are primarily driving the lymphedema market. In addition to this, the rising incidences of several associated risk factors, including trauma to the lymphatic system, such as a sports injury or a burn, obesity, advancing age, gene mutation, etc., are also bolstering the market growth. Furthermore, the widespread adoption of decongestive lymphedema therapy for treating a moderate-to-severe disease condition is acting as another significant growth-inducing factor. This technique helps to reduce fibrosclerotic tissue, enhance skin appearance, promote lymph mobility, lower the risk of infection, boost overall health, etc. Additionally, the escalating demand for microsurgical procedures, such as vascularized lymph node transfer and lymphaticovenous anastomoses, that can improve physiologic drainage of the lymphatic fluid among patients is also creating a positive outlook for the market. Moreover, the inflating utilization of low-level laser therapy to decrease excess protein and fluid built up in soft tissues and reduce inflammation is further augmenting the market growth. Apart from this, the emerging popularity of bioimpedance spectroscopy, which is a simple, quick, and non-invasive method to accurately measure the amount of fluid in a limb with greater sensitivity, is expected to drive the lymphedema market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the lymphedema market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for lymphedema and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the lymphedema market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the lymphedema market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the lymphedema market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current lymphedema marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the lymphedema market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the lymphedema market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the lymphedema market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of lymphedema across the seven major markets?
• What is the number of prevalent cases (2018-2034) of lymphedema by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of lymphedema by gender across the seven major markets?
• What is the number of prevalent cases (2018-2034) of lymphedema by type across the seven major markets?
• How many patients are diagnosed (2018-2034) with lymphedema across the seven major markets?
• What is the size of the lymphedema patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of lymphedema?
• What will be the growth rate of patients across the seven major markets?
   

Lymphedema: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for lymphedema drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the lymphedema market?
• What are the key regulatory events related to the lymphedema market?
• What is the structure of clinical trial landscape by status related to the lymphedema market?
• What is the structure of clinical trial landscape by phase related to the lymphedema market?
• What is the structure of clinical trial landscape by route of administration related to the lymphedema market?